We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Product Recall for Husqvarna Aspire Pruner P5-P4A (pruner) and PE5-P4A (pruner plus extension pole) presenting a risk of injuries.
Product recall for Petzl Pirana Descenders presenting a risk of drowning from in certain situations, as the rope runs quickly through the descender and can accidentally get blocked in the PIRANA’s blocking slot.
Employment Appeal Tribunal Judgment of Judge Barklem on 25 August 2023.
Protected wine name with Protected Geographical Indication (PGI)
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
Increase the frequency of blood pressure monitoring to at least weekly for the first 2 months, and then monitor monthly for the first year and periodically thereafter during treatment, following recent reports of onset of severe hypertension (including rare cases...
Interrupt treatment if posterior reversible encephalopathy syndrome (PRES) is confirmed and resume treatment only once the event is resolved and the benefit of continued treatment outweighs the risk of PRES.
Upper Tribunal Tax and Chancery decision of Judge Herrington on 18 February 2022
Healthcare professionals should be aware of this risk when prescribing prasugrel.
New clinical trial information is available on the timing of the loading dose of prasugrel when used in patients with unstable angina or non-ST segment elevation myocardial infarction.
There is an increased risk that some patients may experience psychiatric symptoms with apremilast, including depression and suicidal thoughts. Stop treatment if patients have new psychiatric symptoms or if existing symptoms worsen.
Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.
Advise patients and their caregivers to seek urgent medical attention if any signs or symptoms of communicating hydrocephalus develop during nusinersen therapy for spinal muscular atrophy. Patients with communicating hydrocephalus may require treatment with a cerebrospinal fluid (CSF) shunt.
The Independent Medicines and Medical Devices Safety Review (IMMDS) has asked the Medicines and Healthcare products Regulatory Agency to place some information on its website. The IMMDS has produced a poster to make sure people are aware of its work...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).